Those mysterious noncoders

Soon after the surprising announcement that the human genome had far fewer genes than most had expected, researchers began to realize that there were still a great many unexplored transcriptional start sites. Tom Gingeras' team at Affymetrix, along with Kevin Struhl of Harvard University and colleagues, confirmed some of these findings in a 2004 Hot Paper by mapping the binding sites for three DNA transcription factors: Sp1, cMyc, and p53. Using a combination of high-density olig

Written byAileen Constans
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Soon after the surprising announcement that the human genome had far fewer genes than most had expected, researchers began to realize that there were still a great many unexplored transcriptional start sites. Tom Gingeras' team at Affymetrix, along with Kevin Struhl of Harvard University and colleagues, confirmed some of these findings in a 2004 Hot Paper by mapping the binding sites for three DNA transcription factors: Sp1, cMyc, and p53. Using a combination of high-density oligonucleotide tiling arrays (in which every region of the genome is represented, thus eliminating bias toward promoter regions) and chromatin immunoprecipitation, they found that roughly 80% of the binding regions were not located at the 5' ends of protein-coding genes, and that many of these binding sites were associated with the noncoding RNAs found in earlier research.1

Struhl says that the results were at first controversial; the paper was originally rejected by Science. "I think ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies